Pharmaceutical and healthcare information provider IMS Health, US, has announced the forthcoming launch of IMS Oncology Quantifier, a comprehensive, clinically rich analytical tool. Available starting in January 2010, IMS Oncology Quantifier enables the company’s clients to assess treatment opportunities and guide commercial decisions in the $48 billion global oncology market.
IMS Oncology Quantifier offers a deeper level of insight into oncology product uptake and treatment patterns, including therapies most often prescribed in leading markets, their effectiveness in treating specific types of cancer, and their impact when used for new or future indications. The offering covers the US, France, Germany, UK, Italy, Spain and Japan, countries that represent more than 90 percent of the global market for cancer treatments.
By integrating IMS’s anonymised patient-level diagnosis and treatment information with product sales data, IMS Oncology Quantifier provides market growth projections and utilisation levels for drugs used to treat 27 types of cancers – organised by tumor type, disease stage, line of therapy and regimen and geography. In addition, the offering measures and assesses the impact of generic and biosimilar oncology treatments, as well as new and future indications for cancer drugs.
IMS Oncology Quantifier combines two of the company’s robust information products, MIDAS and Oncology Analyzer, to accurately measure treatment patterns and advance market research initiatives. The offering is the latest addition to IMS Specialty Solutions, a portfolio of next-generation market intelligence services focused exclusively on specialty pharmaceutical market requirements and challenges. They are a core component of the company’s New Models, New Metrics program, which provides market measurement services to help clients better navigate today’s dynamic healthcare environment.
Search for more such Oncology related products in K-Store
Discuss this NEWS
